This was the stock's third consecutive day of losses.

Shares of Akero Therapeutics, Inc. (AKRO) jumped 3% on Friday afternoon after Jefferies said the company has a “promising” ...

Since McKinney Health burst onto the scene in 2022, it has been carving out its place at the intersection of health and life.

UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $190.82, a high estimate of ...

Shares of Biogen Inc. BIIB shed 1.79% to $133.06 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the Dow Jones Industrial Average DJIA remaining mostly ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM ET. Company Participants. Robin C. Kramer - Executive VP & CFO. Conference ...

Bachleda, PharmD, MBA appointed as independent member of the Board of Directors; David Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and ...

Biogen Inc. has disclosed non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of stroke, psoriasis, arthritis, pain, silicosis, alopecia and more.